nmo add growth lever pt
week announc posit prevent top-lin dataa phase soliri
neuromyel optica spectrum disord nmosd posit surpris mani
latest string win compani see thought
soliri data success nmosd ad upsid launch soliri
gmg provid good momentum alreadi differenti growth profil view
nmosd gmg peak potenti notabl dont believ
difficult achiev indic view alexion core complement
franchis includ phase ahu data pnh pdufa date feb
highli competit despit asset develop importantli
portfolio diversif happen rapid pace acquisit see
addit thought syntimmun acquisit overal think
alexion remain one compel name biotech given mani posit
fundament develop year modest multipl expans
increas pt reflect nmosd increas forecast
host call today neurologist prevent particip
et discuss prevent data soliri implic us
ou passcod slide made avail
increas soliri forecast top/bottom-lin upsid increas soliri
forecast includ nmosd peak lead
higher non-gaap ep consensu
year revenu compound-annual-growth-rate non-gaap ep among highest
biotech vertex higher good upsid potenti
npv impact price target base sotp npv analysi deriv
valu soliri share strensiq
kanuma net cash
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
growth soliri pnh/ahu growth driven
sale refractori gmg assum
approv extend dose option
pnh ahu support long-term
viabil complement franchis recent fx
improv
greater expect growth soliri current
indic ahu pnh gmg label
expans soliri nmo posit data
rapid uptak iv
subcutan formul support upsid case
biosimilar competit soliri
time frame high price pressur ww
geographi addit failur
pnh ahu increas fx headwind
macroeconom issu support downsid case
price target chang price target vs prior base sum-of-th
part npv analysi forecast sale soliri strensiq
kanuma includ termin valu use discount rate vs prior
soliri strensiq kanuma forecast period think
appropri reflect risk portfolio termin valu assum less
growth rate discount rate deriv valu vs
prior soliri share strensiq
kanuma combin net cash vs prior
reflect deal week syntimmun result total npv share
except per op analysisoldnewoldnewr barclay
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
